FDA Denied: Federal Judge Grants Amarin Permission to Promote Fish Oil Drug
A Federal judge in New York today granted Amarin Pharma’s request for an injunction against the enforcement by the U.S. Food & Drug Administration of rules that would otherwise prohibit the communication to physicians of truthful information about unapproved uses of its product Vascepa® (isocapent ethyl).
Today’s ruling follows the 2012 opinion by the U.S. 2nd Circuit Court of Appeals in United States v. Caronia that tossed out a misbranding conviction on the basis of the promotion of Jazz Pharmaceutical’s drug Xyrem® (sodium oxybate) by a sales representative for conveying truthful and non-misleading information to doctors.
Help employers find you! Check out all the jobs and post your resume.
Today’s ruling follows the 2012 opinion by the U.S. 2nd Circuit Court of Appeals in United States v. Caronia that tossed out a misbranding conviction on the basis of the promotion of Jazz Pharmaceutical’s drug Xyrem® (sodium oxybate) by a sales representative for conveying truthful and non-misleading information to doctors.
Help employers find you! Check out all the jobs and post your resume.